(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date 21 December 2000 (21.12.2000)

PCT

(10) International Publication Number WO 00/77031 A3

(51) International Patent Classification²: C07K 7/08, 14/47, C12N 15/10, A61P 35/00

(21) International Application Number: PCT/CA00/00711

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

. ,

Lugion

(30) Priority Data: 60/139,263

15 June 1999 (15.06.1999) US

- (71) Applicant (for all designated States except US): UNIVER-SITY HEALTH NETWORK [CA/CA]; Room 7-504, 610 University Avenue, Toronto, Ontario M5G 2M9 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GARIEPY, Jean [CA/CA]; 29 Elmsthorpe Avenue, Toronto, Ontario M5P 2L5 (CA). YANG, Shaoxian [CA/CA]; 309-36 Thorn-cliffe Park Drive, Toronto, Ontario M4H 1J8 (CA).
- (74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- (88) Date of publication of the international search report: 19 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUCI LIGANDS

(57) Abstract: Novel ligands that bind to MUC1 are disclosed. The ligands were isolated using an improved phage display technique using MUC1 tandem repeat as a target. Uses of the ligand to detect, monitor or treat cancer as well as to prepare antibodies is also described.

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 00/00711

a. classification of subject matter 1PC 7 C07K7/08 C07K14/47 C12N15/10 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C07K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, CHEM ABS Data, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category 5 Citation of document, with Indication, where appropriate, of the relevant passages Relevant to claim No. P,X "Identification of GARIEPY JEAN ET AL: 1-33 short peptide ligands that bind specifically to the breast tumor-associated MUC1 epitope." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), pages 101-102, XP000949494 91st Annual Meeting of the American Association for Cancer Research.; San Francisco, California, USA; April 01-05. 2000, March, 2000 ISSN: 0197-016X abstract -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the International search report 05. 01. 2001. 28 September 2000 Name and mailing address of the ISA Authorized officer -European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Cervigni, S

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 90/00711

| ategory * | Action) DOCUMENTS CONSIDERED TO BE RELEVANT | TEN TOTAL |
|---|--|-------------------------|
| menona . | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| (| WO 96 09411 A (CYTOGEN CORP) 28 March 1996 (1996-03-28) Seg Id No 64 | 1-3,8, 15-33 |
| | abstract; claims; example 6.2; table 7 | |
| x | MANOUTCHARIAN KAREN ET AL: "Characterization of cerebrospinal fluid antibody specificities in neurocysticercosis using phage display peptide library." CLINICAL IMMUNOLOGY (ORLANDO), vol. 91, no. 1, April 1999 (1999-04), pages 117-121, XP000946486 ISSN: 1521-6616 Phage A12 abstract; table 2 | 1-3,8-10 |
| l . | and the court of | 20-26 |
| x | WO 92 18534 A (ANTISOMA LTD) 29 October 1992 (1992-10-29) | 1-3, 16-19, 28-33 |
| | abstract; claims page 7, paragraph 1; example 3; table 6 | 20 33 |
| A | LAING P ET AL: "SELECTION OF PEPTIDE LIGANDS FOR THE ANTIMUCIN CORE ANTIBODY C595 USING PHAGE DISPLAY TECHNOLOGY: DEFINITION OF CANDIDATE EPITOPES FOR A CANCER VACCINE" JOURNAL OF CLINICAL PATHOLOGY, GB, LONDON, vol. 48, no. 3, 1995, pages M136-M141, XP000906851 ISSN: 0021-9746 | |
| A | WO 97 11715 A (AUSTIN RESEARCH INST; SANDRIN MAURO SERGIO (AU); MCKENZIE IAN FARQ) 3 April 1997 (1997-04-03) | |
| A | APOSTOLOPOULOS V ET AL: "CELLULAR MUCINS: TARGETS FOR IMMUNOTHERAPY" CRITICAL REVIEWS IN IMMUNOLOGY,XX,CRC PRESS, INC, vol. 14, no. 3/04, 1994, pages 293-309, XP002071247 ISSN: 1040-8401 | |
| · • • • • • • • • • • • • • • • • • • • | | |

INTERNATIONAL SEARCH REPORT

International application No. PCT/CA 00/00711

| B x I Observations where certain claims were found unsearchabl (Continuation 1 item 1 of first sheet) | | | | | | |
|---|--|--|--|--|--|--|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | | | | |
| Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: | | | | | | |
| Although claim 29 is directed at least in part to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. | | | | | | |
| 2. X Claims Nos.: Because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210 | | | | | | |
| See FORIBER INFORMATION SHEEL FC1/13A/210 | | | | | | |
| 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). | | | | | | |
| Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) | | | | | | |
| This International Searching Authority found multiple inventions in this international application, as follows: | | | | | | |
| see additional sheet | | | | | | |
| As all required additional search fees were timely paid by the applicant, this international Search Report covers at | | | | | | |
| searchable claims. | | | | | | |
| As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. | | | | | | |
| | | | | | | |
| As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: | | | | | | |
| · | | | | | | |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | | | | | | |
| see further information sheet, invention 1 | | | | | | |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. | | | | | | |
| No protest accompanied the payment of additional search fees. | | | | | | |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8

Claim 8 relates to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Moreover, a preliminary search for peptides containing the sequence Pro-Aaa-Pro has given more than 150.000 compounds disclosed in the prior art.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely to the compounds disclosed in claims 9-10 and extended to those containing the sequence Pro-Aaa-Pro prepared in the examples and/or listed in claim 15.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8-10, 20-26 (all complete); 1-3, 15-19, 27-33 (all partially)

Isolated and purified ligands that bind to MUC1 comprising the sequence Pro-Aaa-Pro, method for their isolation, uses in therapy and diagnostics and antibodies binding them.

2. Claims: 4-7, 11-14 (all complete); 1-3, 15-19, 27-33 (all partially)

Isolated and purified ligands disclosed in claim 1, as far as not covered by subject 1, their uses in therapy and diagnostics and antibodies binding them.

===

)

INTERNATIONAL SEARCH REPORT

information on patent family members

PCT/CA 00/00711

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|------------------|---|--|
| WO 9609411 | A | 28-03-1996 | US 5885577 A AU 3719395 A CA 2200684 A CZ 9700855 A EP 0789783 A JP 10506463 T US 6015561 A ZA 9507989 A | 23-03-1999 09-04-1996 28-03-1996 14-01-1998 20-08-1997 23-06-1998 18-01-2000 18-04-1996 |
| WO 9218534 | A | 29-10-1992 | AT 159727 T DE 69222956 D DE 69222956 T DK 672063 T EP 0672063 A ES 2111066 T GB 2270078 A,B GR 3025982 T JP 6506927 T US 5591593 A US 6107469 A US 5833943 A | 15-11-1997 04-12-1997 09-04-1998 18-05-1998 20-09-1995 01-03-1998 02-03-1994 30-04-1998 04-08-1994 07-01-1997 22-08-2000 10-11-1998 |
| WO 9711715 | A | 03-04-1997 | AU 7079396 A AU 707223 B AU 7079496 A WO 9711963 A CA 2233447 A EP 0859627 A JP 2000506493 T | 17-04-1997 08-07-1999 17-04-1997 03-04-1997 03-04-1997 26-08-1998 30-05-2000 |